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ﺍﻟﻤﻠﺨﺺ
ﺃﻫﺪﺍﻑﺍﻟﺒﺤﺚ:ﻳﻬﺪﻑﻫﺬﺍﺍﻟﺒﺤﺚﺇﻟﻰﺗﻘﻴﻴﻢﻗﺪﺭﺓﺍﻟﺤﻘﻦﺍﻟﻤﻨﻐﺮﺱﺍﻟﻘﺎﺑﻞﻟﻠﺘﺤﻠﻞ
ﺍﻟﻤﺤﻤﻞﺑﺎﻟﺪﻭﺍﺀ5ﻓﻠﻮﺭﻭﻳﻮﺭﺍﺳﻴﻞﻣﻦﺗﺤﻘﻴﻖﺃﻗﺼﻰﻗﺪﺭﻣﻦﺍﻟﺘﻌﺮﺽﺍﻟﻤﻮﺿﻌﻲ
ﻣﻦﺍﻟﺪﻭﺍﺀﻣﻊﺍﻟﺤﺪﻣﻦﺳﻤﻴﺘﻪﺍﻟﺠﻬﺎﺯﻳﺔﻓﻲﺍﻟﻔﺌﺮﺍﻥﺍﻟﻤﺼﺎﺑﺔﺑﺴﺮﻃﺎﻥﺍﻟﻜﺒﺪﺍﻟﻤﺴﺘﺤﺚ.
ﻃﺮﻕﺍﻟﺒﺤﺚ:ﺑﻌﺪﺇﺣﺪﺍﺙﺳﺮﻃﺎﻥﺍﻟﻜﺒﺪﻓﻲﻓﺌﺮﺍﻥﻭﻳﺴﺘﺎﺭﺍﻟﺬﻛﻮﺭﺑﻨﺠﺎﺡﺑﺎﺳﺘﺨﺪﺍﻡ
ﺑﺮﻭﺗﻮﻛﻮﻝﻣﺨﺘﺎﺭﺗﻠﻰﺫﻟﻚﻏﺮﺱﻏﺮﺳﺔﻣﺤﻤﻠﺔﺏ5-ﻓﻠﻮﺭﻭﻳﻮﺭﺍﺳﻴﻞﺍﻟﻘﺎﺑﻞﻟﻠﺘﺤﻠﻞ.
ﺛﻢﺗﻢﺫﺑﺢﺍﻟﻔﺌﺮﺍﻥﻋﻠﻰﻓﺘﺮﺍﺕﺯﻣﻨﻴﺔﻣﺘﻔﺮﻗﺔﻭﺗﻢﺗﺠﻤﻴﻊﺍﻟﺪﻡﻭﺍﺳﺘﺨﺪﺍﻣﻪﻷﺩﺍﺀﻣﺨﺘﻠﻒ
ﺍﻟﺘﺠﺎﺭﺏ،ﻛﻤﺎﺗﻢﺍﺳﺘﺮﺟﺎﻉﺍﻟﻐﺮﺳﺎﺕﻭﺗﺤﻠﻴﻠﻬﺎﻟﺤﺴﺎﺏﻛﻤﻴﺔﺍﻟﺪﻭﺍﺀﺍﻟﻤﺘﺒﻘﻲﻓﻴﻬﺎ
ﺑﺎﺳﺘﺨﺪﺍﻡﺟﻬﺎﺯﻗﻴﺎﺱﻟﻮﻥﺍﻟﺴﻮﺍﺋﻞﻋﺎﻟﻲﺍﻟﻀﻐﻂ.ﻭﺃﺟﺮﻳﺖﺃﻳﻀﺎﺩﺭﺍﺳﺔﻟﻠﻜﺒﺪ
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Abstract
Objectives: The objective of this research was to assess abil-
ity of biodegradable implantable 5-Fluorouracil dosage
forms, to maximize the regional exposure of the drug while
limiting its systemic toxicity in rats with induced liver cancer.
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Methods: Liver cancer was successfully induced in male
Wistar rats using a selected protocol followed by surgical
implantation of prepared 5-FU biodegradable implant. Rats
were sacrificed at time intervals and the pooled blood used to
perform the different tests and the implant was retrieved, and
analyzed to calculate the amount of drug left in implant. The
amount of 5-FU in blood was quantified using high pressure
liquid chromatography (HPLC). Gross examination of rat
liver, calculation of liver to body weight percentage, and
complete blood picture analysis were also performed. Liver
biopsies were examined to assess signs of liver necrosis.
Results: Localized necrotic areas were noted in rat liver
biopsies after 5 days with a perimeter of 0.3 to 0.6 cm around
the implants indicating the localized 5-FU therapeutic effect.
Sustained drug release was detected in rats for about
2 months and the amount of 5-FU released from implant into
the systemic circulation was found to represent less than
13%.
Conclusion: PLA coated injection molded implants loaded
with 5-FU could present a promising dosage form for liver
cancer treatment.
Keywords: Anticancer; In vivo; Poly-L-lactic acid (PLA); Wistar
rats
 2014 Taibah University. Production and hosting by Elsevier
Ltd. All rights reserved.
A.F. Hanafy et al. 15time. This would help to augment the therapeutic effect of
chemotherapy together with minimizing the possible toxic side
effect.4 5-Fluorouracil (5-FU) was selected as a model chemo-
therapeutic drug as it is one of the widely used anticancer
drugs for liver cancer treatment.5
This research work aimed to assess ability of implantable
dosage forms in liver cancer region, manufactured using biode-
gradable polymers like Polylactic acid (PLA) and loaded with
5-Fluorouracil, to concentrate 5-FU in liver cancer region, and
decrease the systemic exposure and side effects in rats with
induced liver cancer.6
Materials and Methods
Materials
PLA was prepared as previously described.6 Methyl nitroso
Urea (MNU), Diethyl nitrosamine (N-Nitrosodiethylamine)
(DEN) No: 7566 and N-(2-fluorenyl)acetamide (AAF)
A7015 were bought from SIGMA, USA. Carbon Tetrachlo-
ride (CCl4) was bought from ADWIC Co. (Elnasr Pharma-
ceutical Chemical Company), Egypt. Ethanol 95%,
Formalin 10%, Dimethyl Sulfoxide (DMSO) (high purity
grade), corn oil, sterile sodium chloride solution 0.9%, hepa-
rin (5000 IU) ampoules (Nile Co.), Nylon sutures, Catalar
anesthesia, Betadine surgical solution, Ciprofloxacin Hydro-
chloride powder (Cipla Co.), Cataflam drops, 5-Fluorouracil
powder (Beckmann Chemikalien KG), trichloroacetic acid
(TCA) (Analar grade), ethyl acetate (Analar grade), sodium
hydroxide (high purity grade), Potassium dihydrogen phos-
phate (Analar grade).
Preparation of 5-FU biodegradable implants
PLA injection molded implant formulation containing an
equivalent amount of 12 mg 5-FU per 120 mg implant
and coated with 200 mg PLA and which produced
in vitro prolonged release for approximately 45 days as
has been previously described.6 PLA implants were steril-
ized using gamma radiation at 25 kGy under air prior to
implantation.7
Induction of liver cancer in Wistar rats
Two different protocols were used to induce liver cancer in
Wistar rats weighing 100 g each. The first protocol included
injecting rats with 60 mg/kg MNU dissolved in sodium citrate
0.01 M pH 6 intraperitonealy (ip injection), on day 26 the in-
jected rats received CCl4 2 mL/kg dissolved in corn oil by
gavage.8 While, the second protocol included injecting rats
with 200 mg/kg DEN (Diethyl nitrosamine) dissolved in
0.9% sodium chloride intraperitonially (ip injection), on days
18.19,20, and 22 a daily gavage dosage 20 mg/kg of 2-AAF
dissolved in DMSO and corn oil, (1:29 V/V) was given to
Wistar rats. On day 21, 2 mL/kg of CCl4 in corn oil was gi-
ven to Wistar rats by gavage.9 On days 42 and 72, 6 rats were
examined from control and treated group using the tests dis-
cussed below to decide if successful induction of liver cancer
occurred. Rats were examined physically for any rat skin col-
or change and for presence of rat fur sheds. Rats were thenIntroduction
Liver cancer is one of the major lethal malignancies worldwide.
The main histological subtype is hepatocellular carcinoma
(HCC), which is derived from hepatocytes, the predominant
epithelial cell type in the liver.1,2 Surgery is the only curative
modality for HCC, if the cancer is localized. Standard chemo-
therapy approaches and external beam radiation for treatment
of HCC have little utility. The liver and its surrounding viscera
are very sensitive to radiation. Thus, the dose required to
achieve a decrease in tumor size will kill the host due to liver
failure. Similarly, chemotherapy as a primary or adjuvant ap-
proach has had no benefit. A good reason for not using stan-
dard chemotherapy is that liver cancer patients often have
marked decrease in their ability to metabolize drugs and thus
often experience significant systemic toxicity.2
The poor efficiency of conventional anticancer drugs can be
explained by the special solid tumor structure like liver and
brain tumors.3 This would prevent anticancer drugs from
reaching the tumor area in required concentration, and the
doses of anticancer drug have to be increased consequently.
However, toxicity is a very limiting factor for most of the che-
motherapeutic agents. Therefore, there is a need for a therapy,
that would be able to concentrate drugs close to the tumor site,
and avoid their too large distribution.3
Local administration of biodegradable polymeric drug
delivery systems can present a promising method that gives
clinicians the opportunity to deliver large dose of chemothera-
peutic drugs close to the tumor site for a prolonged period of
ests performed on rats with induced liver cancer
ats were examined and then sacrificed at selected time inter-
als to be in accordance with in-vitro studies performed previ-
usly at 5, 15, 30, 45 and 60 days.6
At each time interval, rats were examined for any physical
hanges especially rat skin color and rat hair. Each rat was
eighed using digital weighing balance and the rat body weight
as recorded (BW). After sacrificing each rat, the liver was dis-
ected fully and separated from any other viscera then weighed
nd the liverweightwas recorded (LW).Liver tobodyweight per-
entage (LB%)was then calculated using the following equation:
B% ¼ LWðgÞ=BWðgÞ  100
Excised liver from the control and treated groups were fixed
sing 10% formalin then dehydrated and embedded in paraffin
ax blocks. They were then cut into 4 lm thick sections fol-
owed by deparaffinization of the sections, staining by hematox-
lin and eosin stain (H&E stain) and examined under light
icroscope. Pooled blood from 3 sacrificed rats from each
roupwas collected in heparinized epindorph tubes then the fol-
owing tests were performed: complete blood count (CBC), liver
nzymes tests (ALT andAST), andmeasurement of the amount
f 5-FU in blood at the different time intervals using HPLC.
Method for detecting and quantification of 5-Fluorouracil in rat
lood after insertion of implantable device in rat liver
n HPLC method for quantification of 5-FU in rat blood was
sed,11 after performing a calibration curve and after testing
rug losses due to binding to protein and other blood compo-
ents. Three milliliter from pooled blood was heparinized in
olypropylene tubes. Heparinized blood was centrifuged at
0,000g for 10 min immediately after collection to separate
lasma. Plasma proteins were then precipitated by addition
f trichloroacetic acid 2 M (5 lL of TCA per 100 lL of plas-
a), and after centrifugation (10,000g, 5 min) plasma samples
ere then stored at 20 C. 5-Fluorouracil was extracted from
lasma samples by ethyl acetate: 100 lL of phosphate buffer
0.5 M, pH 8) and 6 mL of ethyl acetate were added to
00 lL of plasma, after vigorous shaking for 5 min and centri-
16 Assess the ability of biodegradablesacrificed, liver sections were H&E (hematoxylin and eosin)
stained and examined by a pathologist to confirm induction
of cancer after the time specified in the protocol and another
3 rats were sacrificed after 1 month at the specified time in
the protocol to confirm the previous results. The following
tests were performed on the sacrificed rats: body weight to li-
ver weight ratio, complete blood count (CBC) on pooled
blood from 3 rats, and liver functions tests (ALT – alanine
aminotransferase and AST – aspartate aminotransferase) on
pooled blood from 3 rats.
Operating on Wistar rats for initiation of therapy using
prolonged release implant loaded with 5-FU10
All instruments used during the operation were sterilized by
autoclaving. All the areas of work and cages were disinfected
using 70% ethyl alcohol. Each rat was given 0.3 mL of keta-
mine and within 2 min the rats were anaesthetised. Hair was
removed from the area of operation; this area was then disin-
fected using Betadine surgical solution. A clean cut was per-
formed using a sterile scalpel beginning from lower than the
thorax, till the liver is clear while cutting both the skin and
abdominal cavity.
Twelve rats with induced liver cancer were used during
this experiment. Biodegradable implant containing 12 mg 5-
FU per 120 mg PLA as previously described,6 was inserted
in the largest lobe of rat liver which is the left lateral lobe
by direct insertion using forceps and with the help of finger
tips as seen in Figure 1. Sutures were performed for the
abdominal cavity using bioabsorbable (Vicryl) sutures and
Nylon sutures for the external skin. The sutures area was
cleaned with Betadine surgical solution. 1.5 g of Ciprofloxacin
HCl powder was dissolved in 500 mL of water, and put in a
teet (beberon) of water which was then given for rats which
have undergone surgery. Each rat was given 4 drops of Cata-
flam solution, 2 times daily for analgesia on the day of oper-
ation after awaking and the day after. Each rat was placed in
a separate cage, food and water were put in a way to help
them feed. Rats began to move after 30 min after surgery,
and after 2 days they were behaving normally as control
group.
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fugation (4000g, 3 min), the organic phase was collected. Or-
ganic phase was evaporated using nitrogen at 55 C, and
then samples were reconstituted with 100 lL of KH2PO4
0.01 M, pH 4, and 5-Fluorouracil concentration in the sample
determined by HPLC using UV–Vis absorbance detector and
computing integrator. The stationary phase used is Spherisorb
ODS2, C18, 5 lm (25 cm  0.46 cm). The eluent was KH2PO4
0.01 M, pH 4. The flow rate was set at 1 mL/min and the detec-
tor wavelength was 266 nm.
For calibration, standards of 0.1–100 lg/mL 5-FU in phos-
phate buffer (1 mM, pH 7.4), as well as drug-free plasma
pooled with known amounts of 5-FU, to obtain a 5-FU con-
centration between 0.01 and 100 lg/mL, were used in a man-
ner similar to the previously used procedure. For calculating
the circulating blood volume of rats, the recommended mean
value of 64 mL/kg of body weight was used.12
Non-compartmental methods can be used to determine cer-
tain pharmacokinetic parameters without deciding on a partic-
ular compartmental model.13 The basic calculations are based
Figure 1: Picture showing rat liver with induced liver cancer and
with an inserted implant for initiation of therapy.
on the area under the plasma concentration versus times curve
(AUC). The AUC can be calculated by the trapezoidal rule.
Scanning electron microscope pictures used to study degradation
of the 5-FU loaded PLA implants at different time intervals
Surface morphology for implants before and during in vivo re-
lease was evaluated by scanning electron microscopy (SEM).
Retrieved implants were dried and sputter-coated with gold
under vacuum using an electron beam (10 kV) to prepare the
sample for Scanning Electron Microscope. The implant
surface was viewed under low (10.6) and high (342)
magnifications and representative photomicrographs were
obtained. The pore morphology and pore size distribution of
the samples were investigated by SEM at 1000 magnification.
SEM pictures of the retrieved implants were compared with
other retrieved implants at different time intervals of in vivo
study.
Results
The tests performed after induction and during treatment of li-
ver cancer at each testing time interval on Wistar rats are dis-
cussed as follows:
Rat physical examination
Physical examination of control group rats and rats group
after induction of liver cancer is presented in Table 1. Physical
examination of rats showed no change in skin/fur color of rats
and no fur shed in both groups. These results signify that
induction of cancer protocol had no effect on rat’s physical
examination.
After initiation of chemotherapy by placement of implant
in rat liver slight yellow skin coloration in all treated rats from
this group was noted after 15 days together with an increase in
hair loss when rats were held by hand for physical examination
but this diminished after 30 days and completely disappeared
after 2 months as shown in Table 1.
Liver weight to body weight percentage
Liver to body weight percentage for control group rats and
rats with induced cancer group are presented in Table 2. The
presented results show that there was slight increase in liver
to body weight percentage after performing induction of liver
cancer protocol. These results are in agreement with the find-
ings of Attarchi et al.14 The results of liver to body weight per-
centage for rats with induced liver cancer after placement of
implant ranged from 3% to 4.2% which when compared with
Table 1: Physical examination results for rats in control group and liver cancer induction group.
Description item Control After
induction
After 5 days of
implantation
After 15 days of
implantation
After 30 days of
implantation
After 2 months of
implantation
Skin color White White White Slight yellow Very slight Yellow White
Hair loss – – – ++ + –
(–) No hair loss, (+) Slight hair loss, (++) increased hair loss.
Table 2: Liver weight to body weight percentage results for rats in control group and liver cancer induction group.
Description item Control After
induction
After 5 days of
implantation
After 15 days of
implantation
After 30 days of
implantation
After 2 months of
implantation
Body weight (g) 160 167 231 210 235 298
Liver weight (g) 5.7 6.1 7 8.1 8.65 7.5
Liver/body weight% 3.56 3.7 3 3.9 3.7 2.5
Table 3: Complete blood picture and liver enzyme results for control rats and rats after induction of liver cancer.
Blood test results Limit Control After
induction
After 5 days of
implantation
After 15 days of
implantation
After 30 days of
implantation
After 2 months of
implantation
Hb (g/dl) 11.3–14.115 14.1 11.5 11.5 13.1 18.1 16.1
RBC (106/lL) 3.5–9.516 4.8 3.8 3.8 4.2 5.3 5.2
Ht (%) 33–4716 43 34 34 39 48 48
Platelets (1000/lL) 120–24017 185 220 220 210 160 85
WBC (10  3 cells/lL) 1.6–9.317 7.3 10.4 10.4 9.1 6.1 3.1
Lymphocytes (%) NLT 80%15 94% 96% 96% 96% 90 94
Neutrophils (%) 13 – 37%15 6% 4% 4% 4% 10 6
Monocytes (%) NMT 15%15 0% 0% 0% 0% 0 0
AST (units/mL) 70–16011 78 113 100 98 119 144
ALT (units/mL) 40–12011 95 104 106 116 121 174
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liver to body weight percentage for control group was 3.56%
and to rats group with induced liver cancer 3.7% showed that
there were no clear variability between these groups.
Complete blood picture and liver enzymes tests
Complete blood picture (CBP) and liver function blood
enzyme tests (AST and ALT) performed on control group
and group with induced liver cancer are presented in Table 3.
The results showed increase by about 40% in AST enzyme and
very slight increase of about 10% in ALT enzyme in the group
of induced liver cancer compared to control group. These re-
sults might signify that there was disturbance in liver functions
caused by the induction of liver cancer.
Liver enzymes test results for rats after placement of im-
plant in rat liver with induced liver cancer showed gradual in-
crease in liver enzymes levels with time when compared to rats
group with induced liver cancer before implantation, AST
level showed approximately 27% increase and ALT level
showed approximately 67% increase after two months of
implantation.
Liver tissue sections examination
Liver biopsy examination was performed for hematoxylin and
eosin (H&E) stained sections from rats of control group or
group with induced liver cancer using light microscope. Exam-
ination of liver biopsy of control group in Figure 2a and b
Figure 2: Control liver biopsy pictures (H&E).
Figure 3: Liver sections for induction of liver cancer using DEN protocol.
Figure 4: Liver section of rat liver after placement of implant for
5 days (H&E, 100).
Figure 5: Liver biopsy for rat liver after placement of implant for
15 days (H&E, 100).
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showed normal liver lobules with central vein and radiating he-
patic columns. Examination of liver biopsy of rats group with
induced liver cancer in Figure 3a and b using DEN protocol
showed well differentiated hepatocellular carcinoma. The
hepatocytes showed loss of lobular organization and the nuclei
were hyperchromatic and some of them contained prominent
nucleoli. Examination of liver biopsy after using MNU
protocol which was also tried for induction of malignant
changes, showed moderate increase in the diameter of nuclei.
The lobular architecture was preserved. No frank malignant
changes were seen. From the above results, the DEN
protocol was found to be successful in achieving induction of
malignant changes and accordingly this protocol was used
throughout the research to induce cancer in Wistar rats used
in this study.
Pathological reports on implants at the different time inter-
vals revealed small areas of necrosis in Figure 4 which signify
slight therapeutic effect in the area of implantation in liver
after 5 days. Figure 5 for liver sections of rats sacrificed after
15 days showed increase in area of necrosis, while liver sections
for rats sacrificed after 30 days in Figure 6 shows the largest
area of necrosis signifying maximum therapeutic effect. Liver
sections in Figure 7 for rats sacrificed after 60 days does not
show increase in necrosis of liver tissue.
Detection and quantification of 5-Fluorouracil in rat blood after
insertion of implantable dosage forms in rat liver with induced
liver cancer
The amounts of 5-Fluorouracil detected in pooled rat blood
samples taken at different time intervals after placement of im-
plant in rat liver with induced liver cancer are presented in Ta-
ble 4. AUC presents the proportionality to the total amount of
drug eliminated from the body and hence absorbed. The total
amount of 5-FU released in rat blood was calculated by com-
paring the total area under curve (AUC) which is 1250 lg h/
mL for single 12 mg IV bolus injection for a 150 g rat contain-
ing an approximate amount of blood 9.6 mL, with the calcu-
lated total AUC from 5-FU for implants at the different
time intervals. AUC for 5-FU calculated by trapezoidal meth-
od was 168.48 lg h/mL and the average total amount of drug
released in rat blood was calculated to be approximately
1.6 mg for 2 months.
Studying implants degradation through scanning electron
microscope pictures
SEM pictures for implants explanted from rat livers at differ-
ent time intervals were used to study in vivo degradation with
time.21 Figure 8 shows SEM pictures for the coated implants
before placement in rat liver which showed smooth surface
and the cut section showed smooth surface with slight protru-
sions which might represent 5-FU particles. Figure 9 shows
SEM pictures for implants explanted after 15 days in liver
rat, these pictures showed smooth external implant surface
with small cracks together with liver tissues attached to the
external surface. These tissues might indicate compatibility of
the polymer implant matrix with the liver tissues, moreover,
few perforations on the surface might indicate that 15 days
of implantation did not cause strong polymer degradation.
Cut section in Figure 9 shows the presence of few perforations
in coat on implant surface and much more perforations in the
inside of implant which might be attributed to drug dissolu-
tion, polymer hydrolysis and degradation due to water diffu-
sion inside the implant.
Figure 10 shows SEM pictures for implants after 30 day
implantation in rat liver. The surface view showed corrugated
Figure 6: Liver biopsy for rat liver after placement of implant for
30 days (H&E, 100).
Figure 7: Liver biopsy for rat liver after placement of implant for
60 days (H&E, 100).
Table 4: Area under the curve and amount of 5-FU detected in blood after placement of implant.
Time (days) Amount of 5-FU
(lg/mL rat blood)
Average rat
weight (g)
Area under curve for amount
of drug in blood (lg h/ml)
Total amount of drug
released in rat blood (mg)
5 0.56 120 168.48 1.6
15 0.12 145
30 0 158
60 0.013 190
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Figure 8: SEM picture for coated implant surface view on the left and cut section view on the right before in vivo experiment.
Figure 9: SEM picture for coated implant surface view on the left and cut section view on the right after 15 days implantation in rat liver.
Figure 10: SEM picture for coated implant surface view on the left and cut section view on the right after 30 days implantation in rat liver.
Figure 11: SEM picture for coated implant surface view on the left and cut section view on the right after 60 days implantation in rat liver.
20 Assess the ability of biodegradable
surface which could be due to start of extensive degradation of
the external coat together with more liver tissues entangled to
the surface. Moreover, the cut section view showed slightly
more extensive perforations due to degradation of implant
core and larger amount of 5-FU released. Figure 11 shows
SEM21 pictures for implants after 60 days, the surface view
showed almost complete coverage with liver tissues and the
cut section shows disappearance of perforations which might
be due to extensive polymer degradation and beginning of
structural collapse. These results are similar to those obtained
by Sastre et al. research work.11
Discussion
The protocol used for induction of liver cancer was selected to
be devoid of partial hepatectomy (PH) step as operation on
rats for two times, one time for induction of cancer and one
time for implantation therapy, might increase the number of
deaths of rats and might have a negative effect on therapeutic
efficiency of the 5-FU loaded PLA implant.
During rat physical examination after placement of implant
in rat liver with induced liver cancer, transient skin yellow col-
oration was noted which might be due to 5-FU localized che-
motherapy on the liver causing transient chemical hepatitis
that might cause disturbance in ALT, AST and bilirubin.18
Slight hair loss was noted, this signifies that some systemic re-
lease of 5-FU occurred which has caused this mild dermato-
logic toxicity.18 These mild side effects showed that this
implant dosage form offered sustained release of drug because
of appearance of side effects only after 15 days and persistence
of these side effects for 30 days.
Complete blood picture results for induction of liver can-
cer showed similar findings as reported by Attarchi et al.14
The CBP test results were within normal reported limits ex-
cept for an increase of about 40% in WBCs’ in the induced
liver cancer group compared to control group. These results
might be caused by the inflammatory process initiated by
the induction of liver cancer.19 The complete blood picture
results for rats after placement of implant in rat liver with in-
duced liver cancer showed increased mylosuppression with
time. Mylosuppression is a condition in which bone marrow
activity is decreased, resulting in fewer red blood cells, white
blood cells, and platelets and it is usually a side effect of
some cancer treatments like 5-FU. Mylosuppression due to
the implant loaded with 5-FU had the greatest impact on
WBC’s and platelets, while it had a minimal or almost no ef-
fect on RBC’s, Hb and Ht%. Though the WBC’s were de-
creased, its count remained within acceptance limits.
Platelets have undergone depression that was lower than rec-
ommended limits after 2 months only.18,20 The mylosuppres-
sion caused by the implant seems to be minimal compared
to the serious mylosuppression reported in references which
can be attributed to the small amount of systemic release
of 5-FU from the implant. Liver enzymes test results after
placement of implant in rat liver with induced liver cancer
are in conformance with researches reporting that 5-FU
localized injection in the liver is usually accompanied with
chemical hepatitis causing elevation of liver enzymes.12 But
in our case the liver enzymes elevations were less than two-
fold that of control which is considered as slight chemical
hepatitis.
Liver tissue sections examination after placement of im-
plant in rat liver with induced liver cancer showed increase
in localized necrosis area of liver tissue around the implant
with time due to 5-FU killing cancer cells. The above results
may signify that implants present a promising dosage form
for localized liver cancer therapy.21
Quantification results of 5-Fluorouracil in rat blood after
insertion of implantable dosage forms in rat liver with induced
liver cancer show that a very low dose was released in rat blood
when compared to the amount of drug loaded per implant
which was 12 mg, and when compared to the recommended
therapeutic dose of 5-FU injected by IV per day which was
1.5 mg for a 150 g21 rat with an average blood volume of
9.6 mL. These results signify the benefit of using implants in
decreasing systemic release of drug and accordingly the associ-
ated side effects compared to IV injection. These results are
conforming to in vivo study performed by He et al.21 that
investigated the toxicities, biodistribution and anticancer effect
of 5-Fluorouracil controlled release implant on Walker 256
carcinosarcoma cells in Wistar rat livers. Results of this study
showed that 5-FU was able to improve effectiveness and min-
imize the systemic toxicity associated with current systemic
therapy of 5-FU.
Studying implant degradation using scanning electron
microscope pictures for implants explanted after 15 days, 30
and 60 days in rat liver as seen in Figures 9–11 respectively,
show increased attachment of liver tissues to implant surface
and extensive degradation with time. Attachment of liver tis-
sues to implants might indicate compatibility of the polymer
implant matrix with the liver tissues.
Conclusions
PLA coated injection molded implants loaded with 5-FU pre-
sented a promising dosage form for liver cancer treatment.22
It showed sustained drug release in rats for about two
months as well as localized drug release in liver with a perim-
eter of 0.3 to 0.6 cm around the implants.23 Moreover,
implants showed very low systemic drug release; only approx-
imately 13% of drug dose reached the blood over 2 months.
The localized necrotic areas seen in the rat liver biopsies after
5 days of implantation indicated localized 5-FU therapeutic
effect.
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